Company: PRGO
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0001585364-25-000014
Chunk: 234

Company: PERRIGO Co plc
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 234
---
 systematic and rational amortization approach$0.6 $0.3 $— $(0.3)Treasury locksAmount of gain or (loss) reclassified from AOCI into earnings$— $— $(0.1)$— Interest rate swap agreementsAmount of gain or (loss) reclassified from AOCI into earnings$— $— $23.5 $— Year Ended December 31, 2022Total amounts of income and expense line items presented on the Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded$4,451.6 $2,996.2 $156.0 $53.1 The effects of cash flow hedging:Gain (loss) on cash flow hedging relationshipsForeign currency forward contractsAmount of gain or (loss) reclassified from AOCI into earnings$1.6 $(4.8)$— $— Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach$(0.5)$(0.2)$— $(1.4)Treasury locksAmount of gain or (loss) reclassified from AOCI into earnings$— $— $(0.1)$— Interest rate swap agreementsAmount of gain or (loss) reclassified from AOCI into earnings$— $— $4.6 $— Net foreign exchange losses totaled $6.5 million, $1.0 million, and $59.9 million for the years ended December 31, 2024, December 31, 2023, and December 31, 2022, respectively. Therein, 2022 included $16.2 million of loss for the change in fair value of the option contracts to hedge the foreign currency exposure of the euro-denominated purchase price for HRA Pharma.

92

Perrigo Company plc - Item 8Note 12

NOTE 12 - INDEBTEDNESS 

Total borrowings are summarized as follows (in millions):Year EndedDecember 31, 2024December 31, 2023Term loansTerm A Loans due April 1, 2027 (1)$446.9 $471.9 Term B Loans due April 1, 2029 (1)982.2 1,386.2 Total term loans$1,429.1 $1,858.1 Notes and bondsCouponDue